Erosive esophagitis and nonerosive reflux disease (NERD): Comparison of epidemiologic, physiologic, and therapeutic characteristics

Journal of Clinical Gastroenterology

Volumn 41, Issue 2, 2007, Pages 131-137

  Fass, Ronnie ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Esophagus; GERD; Heartburh

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE;

BODY MASS; BODY WEIGHT; CLINICAL FEATURE; CLINICAL TRIAL; DEMOGRAPHY; DRUG DOSE COMPARISON; ESOPHAGUS; ESOPHAGUS DISEASE; ESOPHAGUS MOTILITY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HIATUS HERNIA; HUMAN; LOWER ESOPHAGUS SPHINCTER; LOWER ESOPHAGUS SPHINCTER PRESSURE; NONEROSIVE REFLUX DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; SEX RATIO; TREATMENT RESPONSE;

ESOPHAGITIS, PEPTIC; GASTROESOPHAGEAL REFLUX; HUMANS;

EID: 33846444341     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000225631.07039.6d     Document Type: Review

References (60)

1. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease-current concepts and dilemmas. Am J Gastroenterol. 2001;96:303-314.
2. Locke G III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112: 1448-1456.
3. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management. The Genval workshop report. Gut. 1999;44:S1-S16.
4. Kiesslich R, Kanzler S, Vieth M, et al. Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy. Dig Dis. 2004;22:221-227.
5. Nakamura T, Shirakawa K, Masuyama H, et al. Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. Aliment Pharmacol Ther. 2005;21:19-26.
6. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172-180.
7. A Gallup Organization National Survey: Heartburn Across America. Princeton: The Gallup Organization Inc; 1988.
8. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976; 21:953-956.
9. Winters C Jr, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 1987;92:118-124.
10. Johansson KE, Ask P, Boeryd B, et al. Oesophagitis, signs of reflux and gastric acid secretion in patients with symptoms of gastrooesophageal reflux disease. Scand J Gastroenterol. 1986;21:837-847.
11. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32:974-979.
12. Jones RH, Hungin AP, Phillips J, et al. Gastro-esophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract. 1995;1:149-154.
13. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther. 1997;11: 765-773.
14. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998;10:119-124.
15. Robinson M, Earnest D, Rodriguez-Stanley S, et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med. 1998;158:2373-2376.
16. Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol. 2005;40:275-285.
17. Chang CS, Poon SK, Lien HC, et al. The incidence of reflux esophagitis among the Chinese. Am J Gastroenterol. 1997; 92:668-671.
18. Lööf L, Götell P, Elfberg B. The incidence of reflux oesophagitis. A study of endoscopy reports from a defined catchment area in Sweden. Scand J Gastroenterol. 1993;28:113-118.
19. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis-a placebo-controlled randomized trial. Aliment Pharmacol Ther. 1999;13:907-914.
20. Smout AJPM. Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther. 1997;11:81-85.
21. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk of gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199-211.
22. Aro P, Ronkainen J, Talley NJ, et al. Body mass index and chronic unexplained gastrointestinal symptoms: an adult endoscopic population based study. Gut. 2005;54:1377-1383.
23. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily; omeprazole 20 mg milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997;32: 965-973.
24. Kuster E, Ros E, Toledo-Pimentel V, et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut. 1994;35:8-14.
25. Isolauri J, Luostarinen M, Isolauri E, et al. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol. 1997;92:37-41.
26. Sontag S, Schnell T, Chejfec G, et al. The benign natural history of GERD: 20 years with rare serious progression [Abstract]. Am J Gastroenterol 1999;94:2601, #109.
27. McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut. 1996;38:481-486.
28. McDougall NI, Johnston BT, Collins JS, et al. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastroenterol Hepatol. 1997;9:1161-1167.
29. Manabe N, Yoshihara M, Sasaki A, et al. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol. 2002;17:949-954.
30. Sampliner RE, Fennerty B, Garewal HS. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc. 1996;44:532-535.
31. Pace F, Porro GB. Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol. 2004;99:946-949.
32. Cameron AJ, Arora AS. Barrett's esophagus and reflux esophagitis: is there a missing link? Am J Gastroenterol. 2002;97:273-278.
33. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology. 1992;103:1241-1245.
34. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut. 2002;50:451-459.
35. Fitzgerald RC, Farthing MJ. The pathogenesis of Barrett's esophagus: a process in continuum or discontinuum. Curr Gastroenterol Rep. 2000;2:421-424.
36. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-831.
37. Theisen J, Stein HJ, Dittler HJ, et al. Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc. 2002;16:671-673.
38. Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 2003;98: S2-S7.
39. Quigley EM. Gastro-oesophageal reflux disease-spectrum or continuum? QJM. 1997;90:75-78.
40. Ho KY, Kang JY. Reflux esophagitis patients in Singapore have motor and acid exposure abnormalities similar to patients in the Western Hemisphere. Am J Gastroenterol. 1999;94:1186-1191.
41. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol. 1999;94:2054-2059.
42. van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology. 2000;119:1439-1446.
43. Martinez SD, Malagon I, Garewal HS, et al. Non-erosive reflux disease (NERD)-is it really just a mild form of gastroesophageal reflux disease (GERD)? [Abstract]. Gastroenterology. 2001;120: A-424, no. 2163.
44. Adachi K, Hashimoto T, Hamamoto N, et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole and rabeprazole. J Gastroenterol Hepatol. 2003;18: 1392-1398.
45. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology. 1996; 111:1192-1199.
46. Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol. 2000;95:3071-3080.
47. Bardhan KD, Hawkey CJ, Long RG, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment Pharmacol Ther. 1995;9:145-151.
48. Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol. 1996;91:1749-1757.
49. Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther. 2001;15:227-231.
50. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96:656-665.
51. Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther. 1996;10:547-555.
52. Miner P Jr, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2002;97:1332-1339.
53. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656-664.
54. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med. 2000;160:1803-1809.
55. Chiba N, De Gara DJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798-1810.
56. van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2004;18:CD002095.
57. Fenton P, Terry ML, Galloway KD, et al. Is there a role for laparoscopic fundoplication in patients with non-erosive reflux disease (NERD)? [Abstract]. Gastroenterology. 2000;118:A-481, no. 2600.
58. Clouse RE, Richter JE, Heading RC, et al. Functional esophageal disorders. In: Drossman D, ed. Rome II: The Functional Gastrointestinal Disorders. 2nd ed. Lawrence, KS: Allen Press Inc; 2000:275.
59. Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537-545.
60. Watson RG, Tham TC, Johnston BT, et al. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux-the "sensitive oesophagus". Gut. 1997;40:587-590.